Unmet Needs Analysis by Therapy Area
A defensible answer to "is this market actually crowded?"
A structured approach to identifying and quantifying unmet medical need by therapy area — for portfolio prioritization, BD targeting and launch positioning.
"Where is the medical and commercial unmet need still real — and not already saturated?"
Most "high unmet need" claims collapse on inspection. A defensible answer triangulates clinical guideline gaps, treated-but-not-controlled cohorts, and pipeline density to expose where unmet need is actually unmet.
“There’s a high unmet need” is the most overused phrase in pharma strategy decks — and the least defensible. The fix is to make unmet need a quantified, multi-source, pipeline-adjusted view.
Three axes, three sources, one haircut
Score every TA on clinical, patient and commercial axes; triangulate guidelines, KOL voices and RWE; then subtract the pipeline candidates likely to land first. The result is a defensible whitespace map — the same map BD, R&D and IC teams can argue from.
From research to operating system
Run the unmet-need view as a quarterly-refreshed system, not a slide-deck deliverable. Pipeline shifts, guideline updates and RWE readouts can change the answer materially every quarter.
What we’re seeing in the data.
Treated-but-not-controlled is the real signal
Patients on therapy who fail to reach guideline targets are the most monetizable unmet need.
Guideline gaps reveal whitespace
Indications without first-line guideline-recommended therapy almost always contain unmet need.
Pipeline density caps "unmet" claims
A "high unmet need" indication with 8 Phase 3 candidates rarely stays unmet by launch.
Symptom burden vs survival burden
Pharma underweights symptom-burden unmet need (fatigue, cognitive, pain) — yet patients pay for it.
How to think about it.
-
01
Score on three axes
Clinical (mortality/morbidity), patient (symptom/QoL), commercial (size, payability).
-
02
Triangulate three sources
Guidelines, KOL interviews, RWE — never one alone.
-
03
Apply pipeline haircut
Subtract Phase 2/3 candidates likely to launch first.
-
04
Localize geographically
Unmet need varies sharply by reimbursement and access geography.
-
05
Quantify with RWE
Treated cohort + outcome failure rate + economic cost = a number.
What separates a good answer from a defensible one.
Always combine KOL interviews with claims data to test claims.
Sometimes the unmet need is a budget constraint, not a clinical gap.
Use RWE endpoints (control, hospitalization, days lost) over only trial endpoints.
Some unmet needs will resolve within 36 months — model that.
Where the signal comes from.
Common questions.
How do we make unmet need defensible?
Triangulate clinical, patient and commercial signals, then haircut by pipeline density and forecast — never argue from a single source.
When is "unmet need" actually price ceiling?
Often. Always test whether the unmet need is clinical or just willingness-to-pay.
Want this answered on your data?
We build decision systems on top of analyses like this — so the next question takes minutes, not weeks.
Talk to a strategist